Eurofins launches new tests and massive capacity for detecting and monitoring new variants of SARS-CoV-2
LUXEMBOURG–(BUSINESS WIRE)–The increasing diversity of SARS-CoV-2 variants and the potential higher infectivity of some new viral strains, underline the need
Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors
Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma.
European Commission’s decision on conditional marketing authorization is expected imminently, after the positive CHMP opinion, which will make BNT162b2 if authorized, the first COVID-19 vaccine available in the European Union.
A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a sub-study of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT), as an academia-industry collaboration (investigator Initiated trial) between Apogenix AG and its scientific consultant Henning Walczak and his teams at the University of Cologne and University College London (UCL).
Baris Erdogan, currently Vice President, Site & Patient Networks, at Clinerion, has been promoted by the Board of Directors to the position of Chief Executive Officer as of January 1st, 2021. After a three-year tenure, Clinerion’s current CEO, Ian Rentsch, has decided to step down for personal reasons and to return to his family in Berlin by the end of January, 2021.
European Commission Exercises Option for Additional 80 Million Doses of Moderna’s COVID-19 Vaccine Candidate
Total of 160 million doses ordered by the European Commission to date CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology
Study showed signs of clinical activity, but failed to meet the primary endpoint of the Phase 2 study Two ongoing
Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces updates to the Company’s Phase III trial design evaluating SNG001 as a treatment for patients with COVID-19 and positive progress on the regulatory path.
Bagsværd, Denmark, 16 December 2020 – Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer’s disease
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose, said Pfizer and BioNTech.